Martin Conmy writes about his experiences at some of the most unusual student societies Oxford has to offer: Tiddlywinks, Quidditch, and the Psychedelic Society.
The day-to-day work of many Norwegian headteachers is characterised by micro-management, unclear lines of accountability and high pressure. This limit..
The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to.
- UNI91103 has been selected as the first agent to be trialed in a study by UK investigators
- If successful, data generated will be used for registration of the product
- The study will include approx.1,500 kidney patients to assess if UNI91103 can prevent patients from contracting symptomatic COVID-19 and / or reduce serious illness and death from the infection
- Kidney patients are considered a high-risk patient population that may not respond well to vaccination
- Niclosamide has been demonstrated to prevent fatal outcomes in an animal model of COVID-19 when administered intranasally
1
HELLERUP, Denmark, Feb. 22, 2021 /PRNewswire/ UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 (intranasal niclosamide) as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.